Last week on the forum, members engaged in a rich exchange of experiences and strategies related to clinical trials. Discussions centered around the practical challenges of managing study timelines and budgets, as well as the evolving role of regulatory affairs in study start-ups. The community also shared insights on improving participant engagement through technology, and there was spirited debate on the best approaches to maintaining compliance with audit trails.
This Week’s Hot Topics
The 17th screen fail before lunch
This thread captures the frustrations and realities of frequent screen failures in trials. It’s a relatable look at how teams handle these setbacks.
Read more here
Trial timeline and budget tracker
Participants are discussing tools and tricks to keep trials on schedule and within budget—a perennial challenge in the field.
Read more here
Who first used sealed envelopes correctly
A bit of historical detective work—members are tracing the origins of using sealed envelopes in trials, a method still valued for its simplicity.
Read more here
From regulatory affairs to study start-up
This discussion explores the transition from regulatory affairs to active study start-up roles, highlighting skills that transfer well.
Read more here
What I look for in entry CTAs
A candid discussion on the essential qualities and skills desired in entry-level Clinical Trial Assistants—a must-read for newcomers.
Read more here
Making ePRO reminders feel human
The conversation here focuses on how electronic patient-reported outcome reminders can be personalized to enhance participant engagement.
Read more here
Inspection-ready eTMF audit trails
This thread addresses the complexities of ensuring electronic Trial Master Files are audit-ready, a crucial compliance aspect.
Read more here
Streamlining SMS outreach and eConsent
Members are sharing experiences on integrating SMS and electronic consent processes to streamline participant communication.
Read more here
Thanks for keeping up with the latest in clinical research. Your contributions and questions continue to enrich our community.